Consolidated Statements Of Cash Flows (USD $)	12 Months Ended		150 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,675,000)	$ (10,915,000)	$ (71,992,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,000	9,000	555,000
Stock-based compensation expense	2,792,000	3,245,000	12,374,000
Non-cash interest expense			4,279,000
Change in fair value of convertible debt instrument			3,426,000
Change in fair value of warrant liabilities		524,000	(9,022,000)
Write off of intangible assets			351,000
Changes in operating assets and liabilities:
Grant receivable		234,000
Prepaid expenses and other assets	(55,000)	(34,000)	(156,000)
Accounts payable and accrued expenses	(577,000)	1,273,000	1,626,000
Other long-term liabilities	6,000	(12,000)	6,000
Net cash used in operating activities	(7,500,000)	(5,676,000)	(58,553,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(5,000)	(5,000)	(431,000)
Change in restricted cash and security deposit	69,000	(10,000)
Increase in patents costs and other assets			(404,000)
Net cash provided by (used in) investing activities	64,000	(15,000)	(835,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants	10,403,000		39,093,000
Net proceeds from issuance of convertible debt instruments			10,621,000
Repayment of convertible debt instruments			(1,641,000)
Net proceeds from exercise of common stock warrants and options		6,067,000	11,293,000
Proceeds from shareholder advances			9,000
Net cash provided by financing activities	10,403,000	6,197,000	68,752,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,967,000	506,000	9,364,000
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	6,397,000	5,891,000
CASH AND CASH EQUIVALENTS, END OF PERIOD	9,364,000	6,397,000	9,364,000
SUPPLEMENTAL DISCLOSURE-Cash paid for interest			114,000
NONCASH FINANCING ACTIVITIES:
Issuance of equity warrants in connection with equity offerings	4,445,000		9,482,000
Conversion of accrued expenses into common stock	26,000		329,000
Cashless exercise of stock options and warrants	235,000	341,000	674,000
Conversion and redemptions of convertible notes and accrued interest into common stock			12,243,000
Conversion of extension costs related to convertible notes into common stock			171,000
Payment of preferred stock dividends in common stock	976,000	1,536,000	4,155,000
Issuance of warrants to induce conversion of notes payable			503,000
Issuance of stock to acquire Pro-Pharmaceuticals-NV			107,000
Series A 12% Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of convertible preferred stock and related warrants			1,691,000
Series B-1 12% Redeemable Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of redeemable convertible preferred stock and related warrants			1,548,000
Series B-2 12% Redeemable Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of redeemable convertible preferred stock and related warrants			3,935,000
Series C Super Dividend Convertible Preferred Stock
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of convertible preferred stock and related warrants		$ 130,000	$ 2,203,000